These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 26563568)

  • 1. Synergistic Activation of Latent HIV-1 Expression by Novel Histone Deacetylase Inhibitors and Bryostatin-1.
    Martínez-Bonet M; Clemente MI; Serramía MJ; Muñoz E; Moreno S; Muñoz-Fernández MÁ
    Sci Rep; 2015 Nov; 5():16445. PubMed ID: 26563568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing.
    Wei DG; Chiang V; Fyne E; Balakrishnan M; Barnes T; Graupe M; Hesselgesser J; Irrinki A; Murry JP; Stepan G; Stray KM; Tsai A; Yu H; Spindler J; Kearney M; Spina CA; McMahon D; Lalezari J; Sloan D; Mellors J; Geleziunas R; Cihlar T
    PLoS Pathog; 2014 Apr; 10(4):e1004071. PubMed ID: 24722454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polyanionic carbosilane dendrimers as a new adjuvant in combination with latency reversal agents for HIV treatment.
    Relaño-Rodríguez I; Juárez-Sánchez R; Pavicic C; Muñoz E; Muñoz-Fernández MÁ
    J Nanobiotechnology; 2019 May; 17(1):69. PubMed ID: 31113488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short Communication: The Broad-Spectrum Histone Deacetylase Inhibitors Vorinostat and Panobinostat Activate Latent HIV in CD4(+) T Cells In Part Through Phosphorylation of the T-Loop of the CDK9 Subunit of P-TEFb.
    Jamaluddin MS; Hu PW; Jan Y; Siwak EB; Rice AP
    AIDS Res Hum Retroviruses; 2016 Feb; 32(2):169-73. PubMed ID: 26727990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiretroviral drugs do not interfere with bryostatin-mediated HIV-1 latency reversal.
    Martínez-Bonet M; Clemente MI; Álvarez S; Díaz L; García-Alonso D; Muñoz E; Moreno S; Muñoz-Fernández MÁ
    Antiviral Res; 2015 Nov; 123():163-71. PubMed ID: 26427554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The thioacetate-ω(γ-lactam carboxamide) HDAC inhibitor ST7612AA1 as HIV-1 latency reactivation agent.
    Badia R; Grau J; Riveira-Muñoz E; Ballana E; Giannini G; Esté JA
    Antiviral Res; 2015 Nov; 123():62-9. PubMed ID: 26348004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combinations of isoform-targeted histone deacetylase inhibitors and bryostatin analogues display remarkable potency to activate latent HIV without global T-cell activation.
    Albert BJ; Niu A; Ramani R; Marshall GR; Wender PA; Williams RM; Ratner L; Barnes AB; Kyei GB
    Sci Rep; 2017 Aug; 7(1):7456. PubMed ID: 28785069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxicity and in vitro activity of HIV-1 latency-reversing agents in primary CNS cells.
    Gray LR; On H; Roberts E; Lu HK; Moso MA; Raison JA; Papaioannou C; Cheng WJ; Ellett AM; Jacobson JC; Purcell DF; Wesselingh SL; Gorry PR; Lewin SR; Churchill MJ
    J Neurovirol; 2016 Aug; 22(4):455-63. PubMed ID: 26727904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone deacetylase inhibitors induce complex host responses that contribute to differential potencies of these compounds in HIV reactivation.
    Beliakova-Bethell N; Mukim A; White CH; Deshmukh S; Abewe H; Richman DD; Spina CA
    J Biol Chem; 2019 Apr; 294(14):5576-5589. PubMed ID: 30745362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection.
    Tsai P; Wu G; Baker CE; Thayer WO; Spagnuolo RA; Sanchez R; Barrett S; Howell B; Margolis D; Hazuda DJ; Archin NM; Garcia JV
    Retrovirology; 2016 May; 13(1):36. PubMed ID: 27206407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bryostatin-1 Decreases HIV-1 Infection and Viral Production in Human Primary Macrophages.
    Hany L; Turmel MO; Barat C; Ouellet M; Tremblay MJ
    J Virol; 2022 Feb; 96(4):e0195321. PubMed ID: 34878918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression.
    Darcis G; Kula A; Bouchat S; Fujinaga K; Corazza F; Ait-Ammar A; Delacourt N; Melard A; Kabeya K; Vanhulle C; Van Driessche B; Gatot JS; Cherrier T; Pianowski LF; Gama L; Schwartz C; Vila J; Burny A; Clumeck N; Moutschen M; De Wit S; Peterlin BM; Rouzioux C; Rohr O; Van Lint C
    PLoS Pathog; 2015 Jul; 11(7):e1005063. PubMed ID: 26225566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients.
    Spivak AM; Bosque A; Balch AH; Smyth D; Martins L; Planelles V
    Antimicrob Agents Chemother; 2015 Oct; 59(10):5984-91. PubMed ID: 26169416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo.
    Bullen CK; Laird GM; Durand CM; Siliciano JD; Siliciano RF
    Nat Med; 2014 Apr; 20(4):425-9. PubMed ID: 24658076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone deacetylase inhibitor chidamide promotes reactivation of latent human immunodeficiency virus by introducing histone acetylation.
    Kuai Q; Lu X; Qiao Z; Wang R; Wang Y; Ye S; He M; Wang Y; Zhang T; Wu H; Ren S; Yu Q
    J Med Virol; 2018 Sep; 90(9):1478-1485. PubMed ID: 29704439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Vitro Reactivation of Replication-Competent and Infectious HIV-1 by Histone Deacetylase Inhibitors.
    Banga R; Procopio FA; Cavassini M; Perreau M
    J Virol; 2016 Feb; 90(4):1858-71. PubMed ID: 26656693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 4-Deoxyphorbol inhibits HIV-1 infection in synergism with antiretroviral drugs and reactivates viral reservoirs through PKC/MEK activation synergizing with vorinostat.
    De la Torre-Tarazona HE; Jiménez R; Bueno P; Camarero S; Román L; Fernández-García JL; Beltrán M; Nothias LF; Cachet X; Paolini J; Litaudon M; Alcami J; Bedoya LM
    Biochem Pharmacol; 2020 Jul; 177():113937. PubMed ID: 32224142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bryostatin-1 synergizes with histone deacetylase inhibitors to reactivate HIV-1 from latency.
    Pérez M; de Vinuesa AG; Sanchez-Duffhues G; Marquez N; Bellido ML; Muñoz-Fernandez MA; Moreno S; Castor TP; Calzado MA; Muñoz E
    Curr HIV Res; 2010 Sep; 8(6):418-29. PubMed ID: 20636281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Combinations of Protein Kinase C Activators and Histone Deacetylase Inhibitors That Potently Reactivate Latent HIV.
    Curreli F; Ahmed S; Victor SMB; Debnath AK
    Viruses; 2020 Jun; 12(6):. PubMed ID: 32503121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 reactivation induced by apicidin involves histone modification in latently infected cells.
    Lin S; Zhang Y; Ying H; Zhu H
    Curr HIV Res; 2011 Jun; 9(4):202-8. PubMed ID: 21631428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.